Therapeutic Area

Cardiology

Therapeutic area intelligence for Cardiology with 17 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 17
Catalysts: 0
Companies: 2

Companies

cardiovascular pharmaceutical companies →

pharma companies with heart failure portfolios →

Assets

Recent signals(17)

RegulatoryJune 21, 2026

Study on Chronic E-Cigarette Usage and Microvascular Health Initiated

A study led by Virginia Commonwealth University is examining the effects of chronic e-cigarette use on microvascular health.

ClinicalJune 21, 2026

Dapagliflozin Evaluated for Right Ventricular-Pulmonary Artery Coupling Post-OPCAB

A study is underway to assess the impact of dapagliflozin on right ventricular-pulmonary artery coupling in heart failure patients post-surgery.

StrategyJune 20, 2026

Cost-effectiveness of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Assessed

The study evaluates the cost-effectiveness of mavacamten combined with standard therapies for symptomatic obstructive HCM.

ClinicalJune 20, 2026

Limited FDA-approved Antihypertensive Therapies for Pediatric Patients Highlighted

There is a significant unmet medical need for antihypertensive therapies in pediatric patients, especially those under six years old.

ClinicalJune 20, 2026

HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management

The HEARTFELT study is assessing the safety and effectiveness of a remote patient monitoring device for heart failure patients.

ClinicalJune 20, 2026

Yale University Launches Digital Health Initiative for Heart Failure in Uganda

Yale University is implementing a digital-first care model for heart failure in Uganda, evaluating its effectiveness through a cluster-randomized trial.

ClinicalJune 19, 2026

Guidance on Distinction Between Angioedema Types for ACE-Inhibitor Users

Healthcare professionals are advised about the delayed onset of angioedema and the differing treatment strategies for bradykinin- versus histamine-mediated cases.

RegulatoryJune 19, 2026

Medline Industries Expands Catheter Recall Due to Infection Risk

Medline Industries has expanded a recall of reprocessed electrophysiology and ultrasound catheters due to potential contamination risks.

ClinicalJune 18, 2026

Study on Riociguat's Impact on Right Heart Function in PAH and CTEPH

A clinical study is underway to assess the effects of riociguat on right ventricular size and function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

ClinicalJune 18, 2026

Digital Management Improves Outcomes in Early Cardiogenic Shock Patients

A clinical trial involving 472 patients with early-stage cardiogenic shock evaluated the HeartMed-HF digital management system, showing potential benefits over standard discharge guidance.

ClinicalJune 18, 2026

Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques

The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.

ClinicalJune 17, 2026

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.

ClinicalJune 17, 2026

Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority

A randomized trial is assessing whether S-ICD implantation without defibrillation testing is non-inferior to the standard method.

ClinicalJune 17, 2026

Study on PSB Pacing to Prevent Atrial Fibrillation in Sinus Node Dysfunction Patients

A clinical trial is evaluating the effectiveness of posterosuperior bundle pacing in reducing atrial fibrillation incidence in patients with sinus node dysfunction.

ClinicalJune 14, 2026

Rivaroxaban Trial for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients

A clinical trial is proposed to evaluate the use of rivaroxaban for stroke prevention in hypertrophic cardiomyopathy patients with abnormal left atrial strain.

ClinicalJune 2, 2026

Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes

This clinical trial will evaluate the impact of avoiding pulmonary artery catheters on recovery outcomes in cardiac surgery patients.

RegulatoryJune 1, 2026

AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment

Baxfendy has been approved in the US as the first and only aldosterone synthase inhibitor for adults with hypertension, showing a significant reduction in systolic blood pressure.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.